Thank you for subscribing!
Finfeed Archived Nov 13, 2018
Clinical stage immuno-oncology company, Imugene Limited (ASX:IMU), today announced preparations are underway to begin the Phase 2 study of its HER-Vaxx cancer vaccine in gastric cancer patients in early 2019.
Finfeed Archived Nov 09, 2018
Imugene Limited (ASX:IMU) has today announced that it has received a research and development (R&D) tax refund of $1.85 million as part of the Australian government’s R&D tax incentive scheme. The incentive recognises the important immuno-oncology research activities undertaken by the ASX small cap during the financial year ended 30 June 2018.
Finfeed Archived Oct 29, 2018
Clinical-stage oncology company, Prescient Therapeutics Ltd (ASX:PTX), has appointed leading drug discovery and development executive, Dr James Winkler, as Vice President for business development based in the US.
Finfeed Archived Oct 24, 2018
Last week, biopharmaceutical drug discovery and development company, Antisense Therapeutics (ASX:ANP) spiked 217% in one day
Get expert stock analysis direct in your inbox
Finfeed Archived Oct 22, 2018
It was a powerhouse week for biotech and pot-stocks, with high impact performances begging the question: is biotech finally back?
Finfeed Archived Oct 17, 2018
The biotech sector was yesterday led by biopharmaceutical drug discovery and development company, Antisense Therapeutics (ASX:ANP) which ended the day 217% higher.
Finfeed Archived Oct 04, 2018
Antisense Therapeutics’ (ASX:ANP) ATL1102 to treat inflammation in boys with Duchenne Muscular Dystrophy (DMD) - one of the most common fatal genetic disorders. It’s caused by a mutation in the muscle dystrophin gene leading to severe progressive muscle loss and premature death.
Join Our Mailing List
